Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Geron Corporation before investing.

In this article, we go over a few key elements for understanding Geron Corporation’s stock price such as:

• Geron Corporation’s current stock price and volume
• Why Geron Corporation’s stock price changed recently
• Upgrades and downgrades for GERN from analysts
• GERN’s stock price momentum as measured by its relative strength

About Geron Corporation (GERN)

Before we jump into Geron Corporation’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company’s product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

Want to learn more about Geron Corporation’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Geron Corporation.

Geron Corporation’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Geron Corporation’s stock price was $1.290.

Geron Corporation is down 3.73% from its previous closing price of $1.340.

During the last market session, Geron Corporation’s stock traded between $1.220 and $1.370. Currently, there are approximately 669.38 million shares outstanding for Geron Corporation.

Geron Corporation’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Geron Corporation Stock Price History

Geron Corporation’s (GERN) price is currently up 0.78% so far this month.

During the month of July, Geron Corporation’s stock price has reached a high of $1.620 and a low of $1.220.

Over the last year, Geron Corporation has hit prices as high as $2.010 and as low as $1.040. Year to date, Geron Corporation’s stock is down 2.27%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Geron Corporation Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there was 1 analyst who downgraded Geron Corporation’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Geron Corporation’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Geron Corporation’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Geron Corporation’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Geron Corporation (GERN) by visiting AAII Stock Evaluator.

Relative Price Strength of Geron Corporation

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Geron Corporation has a weighted four-quarter relative price strength of -4.54%, which translates to a Momentum Score of 37 and is considered to be Weak.

Want to learn more about how Geron Corporation is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Geron Corporation Stock Price: Bottom Line

As of July 31, 2026, Geron Corporation’s stock price is $1.290, which is down 3.73% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Geron Corporation stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.